Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.37 |
| ▸ | LOX | P28300 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21753223 | 0.86 | PTGS2 (0.51) | PTGS2PTGS1KCNH2 | |
| SCHEMBL12094201 | 0.82 | PTGS2 (0.54) | PTGS2PTGS1MBOAT4HTR2AHTR2C | |
| SCHEMBL23530021 | 0.81 | PTGS2 (0.43) | PTGS2PTGS1MBOAT4HTR2AHTR2C | |
| SCHEMBL568140 | 0.81 | LOXL2 (0.47) | PTGS2PTGS1MBOAT4HTR2AHTR2C | |
| SCHEMBL7904034 | 0.80 | PTGS1 (0.40) | PTGS2PTGS1MBOAT4HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL560818 | 0.79 | LOXL2 (0.49) | PTGS2PTGS1MBOAT4HTR2AHTR2C | |
| SCHEMBL24612155 | 0.79 | MBOAT4 (0.44) | PTGS2PTGS1MBOAT4HTR2AHTR2C | |
| SCHEMBL15491212 | 0.78 | MBOAT4 (0.43) | PTGS2PTGS1MBOAT4HTR2AHTR2C | |
| SCHEMBL13553361 | 0.77 | PTGS2 (0.43) | PTGS2PTGS1MBOAT4HTR2AHTR2C | |
| SCHEMBL18457325 | 0.77 | PTGDR2 (0.45) | PTGS2PTGS1MBOAT4GPR119ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332459-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2022-05-17 | — | — | US | disclosed |
| EP-3177611-B1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION AS (DK) | 2021-10-06 | — | — | EP | disclosed |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-10689383-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | NUEVOLUTION A/S (DK) | 2020-06-23 | — | — | US | disclosed |
| US-10689383-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | NUEVOLUTION A/S (DK) | 2020-06-23 | — | — | US | disclosed |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| EP-2766366-B1 | TETRAHYDROTRIAZOLOPYRIMIDINE DERIVATIVES AS HUMAN NEUTROPHIL ELASTASE INHBITORS | CHIESI FARMA SPA (IT) | 2016-11-09 | — | — | EP | disclosed |
| CN-103827117-B | Tetrahydrochysene triazolopyrimidine derivative as people's inhibitors of neutrophil elastase | 奇斯药制品公司 | 2016-08-24 | — | — | CN | disclosed |
| US-9023855-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-05-05 | — | — | US | disclosed |
| EP-2766366-A1 | TETRAHYDROTRIAZOLOPYRIMIDINE DERIVATIVES AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2014-08-20 | — | — | EP | disclosed |
| US-20140179714-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-26 | — | — | US | disclosed |
| CN-103827117-A | Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors | CHIESI FARMA SPA | 2014-05-28 | — | — | CN | disclosed |
| WO-2013037809-A1 | TETRAHYDROTRIAZOLOPYRIMIDINE DERIVATIVES AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-03-21 | — | — | WO | disclosed |
| US-20130065913-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689383-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | RORA, RORC, RORB | PTGS2 1179/4885PTGS1 875/4885MBOAT4 3845/4885 |
| US-20130065913-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | PTGS2 815/4885PTGS1 291/4885MBOAT4 2990/4885 |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | TRPC6, TRPV6, TRPM6 | PTGS2 1232/4885PTGS1 1179/4885MBOAT4 3725/4885 |
| US-20140179714-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | PTGS2 815/4885PTGS1 291/4885MBOAT4 2989/4885 |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | PPARD, PPARG, RORC | PTGS2 893/4885PTGS1 799/4885MBOAT4 3862/4885 |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TRPC6, TRPV6, TRPM6 | PTGS2 1232/4885PTGS1 1179/4885MBOAT4 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.